|
|
Blood, 1 June 2005, Vol. 105, No. 11, pp. 4492-4499.
Prepublished online as a Blood First Edition Paper on February 3, 2005; DOI 10.1182/blood-2004-08-2985.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Multifunctional role of Erk5 in multiple myeloma
Xonia Carvajal-Vergara,
Soraya Tabera,
Juan C. Montero,
Azucena Esparís-Ogando,
Ricardo López-Pérez,
Gema Mateo,
Norma Gutiérrez,
Marisa Parmo-Cabañas,
Joaquín Teixidó,
Jesús F. San Miguel, and
Atanasio Pandiella
From the Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Spain; Hospital Universitario de Salamanca, Spain; and Centro de Investigaciones Biológicas, Madrid, Spain.
Multiple myeloma is characterized by the accumulation of terminally differentiated B cells in the bone marrow, due to increased proliferation and restricted apoptosis of the myelomatous clone. Here we have studied the participation of a novel mitogen-activated protein kinase (MAPK) route, the extracellular signal-regulated kinase 5 (Erk5) pathway, in the regulation of myeloma cell proliferation and apoptosis. Erk5 was expressed in cells isolated from patients and in myeloma cell lines. The myeloma growth factor interleukin 6 (IL-6) activated Erk5, and this activation was independent of Ras and Src. Expression of a dominant-negative form of Erk5 restricted the proliferation of myeloma cells and inhibited IL-6–dependent cell duplication. This dominant-negative form also sensitized myeloma cells to the proapoptotic action of dexamethasone and PS341. The latter compound caused a profound decrease in the amount of endogenous Erk5 and was less effective in inducing apoptosis when the level of Erk5 was increased by transfection of Erk5. These results place the Erk5 route as a new regulatory signaling pathway that affects multiple myeloma proliferation and apoptosis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. S. Mitsiades, E. M. Ocio, A. Pandiella, P. Maiso, C. Gajate, M. Garayoa, D. Vilanova, J. C. Montero, N. Mitsiades, C. J. McMullan, et al.
Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
Cancer Res.,
July 1, 2008;
68(13):
5216 - 5225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Montero, R. Lopez-Perez, J. F. San Miguel, and A. Pandiella
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity
Haematologica,
June 1, 2008;
93(6):
851 - 859.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Colado, S. Alvarez-Fernandez, P. Maiso, J. Martin-Sanchez, M. B. Vidriales, M. Garayoa, E. M. Ocio, J. C. Montero, A. Pandiella, and J. F. San Miguel
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
Haematologica,
January 1, 2008;
93(1):
57 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-O. Lui, N. Pourmand, B. K. Patterson, and A. Fire
Patterns of Known and Novel Small RNAs in Human Cervical Cancer
Cancer Res.,
July 1, 2007;
67(13):
6031 - 6043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagel, C. Burek, L. Venturini, M. Scherr, H. Quentmeier, C. Meyer, A. Rosenwald, H. G. Drexler, and R. A. F. MacLeod
Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1
Blood,
April 1, 2007;
109(7):
3015 - 3023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Garaude, S. Cherni, S. Kaminski, E. Delepine, C. Chable-Bessia, M. Benkirane, J. Borges, A. Pandiella, M. A. Iniguez, M. Fresno, et al.
ERK5 Activates NF-{kappa}B in Leukemic T Cells and Is Essential for Their Growth In Vivo
J. Immunol.,
December 1, 2006;
177(11):
7607 - 7617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Maiso, X. Carvajal-Vergara, E. M. Ocio, R. Lopez-Perez, G. Mateo, N. Gutierrez, P. Atadja, A. Pandiella, and J. F. San Miguel
The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance
Cancer Res.,
June 1, 2006;
66(11):
5781 - 5789.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
